Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives
出版年份 2020 全文链接
标题
Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives
作者
关键词
Lung cancer, Mutations, Gene rearrangements, Predictive markers, Therapy, PCR, NGS, Review
出版物
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 157, Issue -, Pages 103194
出版商
Elsevier BV
发表日期
2020-12-12
DOI
10.1016/j.critrevonc.2020.103194
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
- (2020) J. Mazieres et al. ANNALS OF ONCOLOGY
- Routine-dose and High-dose Icotinib in Advanced Non-Small Cell Lung Cancer Patients harboring EGFR Exon 21 L858R Mutation: the Randomized, Phase II, INCREASE Trial
- (2020) Xi Li et al. CLINICAL CANCER RESEARCH
- Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer
- (2020) Kohsuke Isomoto et al. CLINICAL CANCER RESEARCH
- Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
- (2020) James Chih-Hsin Yang et al. Journal of Thoracic Oncology
- Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing
- (2020) Danielle Cohen et al. Journal of Thoracic Oncology
- Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in non-small cell lung cancer
- (2020) Weihua Li et al. Journal of Thoracic Oncology
- Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
- (2020) Alexander Drilon et al. NATURE MEDICINE
- The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal
- (2020) Valerio Gristina et al. CANCER TREATMENT REVIEWS
- Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
- (2020) Iosune Baraibar et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2020) Shirish Gadgeel et al. JOURNAL OF CLINICAL ONCOLOGY
- The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer
- (2020) Matthew P. Smeltzer et al. Journal of Thoracic Oncology
- Brief Report: Comparison of three sequencing panels used for the assessment of tumor mutational burden in non-small cell lung cancer demonstrates low comparability.
- (2020) Simon Heeke et al. Journal of Thoracic Oncology
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- (2020) Paul K. Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- Is tissue still the issue in detecting molecular alterations in lung cancer?
- (2020) Chong‐Kin Liam et al. RESPIROLOGY
- HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
- (2020) Bob T. Li et al. Cancer Discovery
- Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
- (2020) M. Schuler et al. ANNALS OF ONCOLOGY
- The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
- (2020) Ravi Salgia et al. CANCER TREATMENT REVIEWS
- The force of HER2 – A druggable target in NSCLC?
- (2020) M. Jebbink et al. CANCER TREATMENT REVIEWS
- Selpercatinib: First Approval
- (2020) Anthony Markham DRUGS
- The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
- (2020) Lynette M. Sholl et al. Journal of Thoracic Oncology
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality
- (2020) Nadia Howlader et al. NEW ENGLAND JOURNAL OF MEDICINE
- Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis
- (2020) Ruth P. Norris et al. BMC Medicine
- Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC
- (2020) Aaron C. Tan et al. Journal of Thoracic Oncology
- EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib
- (2020) Niamh Coleman et al. Journal of Thoracic Oncology
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- (2020) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1
- (2020) Evgeny N. Imyanitov et al. Frontiers in Oncology
- Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
- (2020) Giuseppe Lamberti et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients
- (2020) Umberto Malapelle et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases
- (2019) Anna-Lena Volckmar et al. INTERNATIONAL JOURNAL OF CANCER
- A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer
- (2019) Jose M. Pacheco et al. Frontiers in Oncology
- Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?
- (2019) Alex Friedlaender et al. Frontiers in Oncology
- Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?
- (2019) Paul Hofman et al. Cancers
- Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma
- (2019) Sylvie Lantuejoul et al. Journal of Thoracic Disease
- Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
- (2019) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
- (2019) Conan G. Kinsey et al. NATURE MEDICINE
- Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study
- (2019) D. Ross Camidge et al. Journal of Thoracic Oncology
- The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer
- (2019) Jong Woo Lee et al. Journal of Thoracic Oncology
- PD-L1 expression, tumor mutational burden and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer
- (2019) Marcelo V. Negrao et al. Journal of Thoracic Oncology
- Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): What to add and what to leave out
- (2019) C. Proto et al. CANCER TREATMENT REVIEWS
- Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
- (2019) Ernest Nadal et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- HER2: defining a Neu target in non-small-cell lung cancer
- (2019) S Ekman ANNALS OF ONCOLOGY
- 111OActivity of larotrectinib in TRK fusion lung cancer
- (2019) A Drilon et al. ANNALS OF ONCOLOGY
- 113OEntrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001
- (2019) L Paz-Ares et al. ANNALS OF ONCOLOGY
- Ultra-sensitive EGFRT790Mdetection as an independent prognostic marker for lung cancer patients harboring EGFRdel19mutations and treated with first-generation TKIs
- (2019) Julie vendrell et al. CLINICAL CANCER RESEARCH
- High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden
- (2019) Ryma Benayed et al. CLINICAL CANCER RESEARCH
- Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small-Cell Lung Cancer
- (2019) Wenfeng Fang et al. CLINICAL CANCER RESEARCH
- ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer
- (2019) Gina Rosas et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer
- (2019) Kurtis D. Davies et al. Journal of Thoracic Oncology
- Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy
- (2019) Haixia Li et al. LUNG CANCER
- Abandoning the Notion of Non-Small Cell Lung Cancer
- (2019) Valeria Relli et al. TRENDS IN MOLECULAR MEDICINE
- ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
- (2019) C Marchiò et al. ANNALS OF ONCOLOGY
- When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
- (2019) Laurent Mhanna et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors
- (2019) Tessa A. Morris et al. DRUGS
- Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study
- (2019) Esther Conde et al. Journal of Thoracic Oncology
- Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness
- (2019) Michela Terlizzi et al. PHARMACOLOGY & THERAPEUTICS
- An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer
- (2019) Brian C. Haynes et al. Translational Oncology
- Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey
- (2019) Jeffrey P. Gregg et al. Translational Lung Cancer Research
- Opportunities of circulating tumor DNA in lung cancer
- (2019) Ting-Hui Wu et al. CANCER TREATMENT REVIEWS
- Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer
- (2019) Kathryn C. Arbour et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer
- (2019) Leora Horn et al. Journal of Thoracic Oncology
- Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens
- (2019) Amanda Vannitamby et al. LUNG CANCER
- A Phase 2 Study of Lenvatinib in Patients With RET Fusion-Positive Lung Adenocarcinoma
- (2019) Toyoaki Hida et al. LUNG CANCER
- Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
- (2019) Narjust Duma et al. MAYO CLINIC PROCEEDINGS
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
- (2019) James P. Solomon et al. MODERN PATHOLOGY
- Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
- (2019) Peter T Harrison et al. SEMINARS IN CANCER BIOLOGY
- Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
- (2019) E J Aguilar et al. ANNALS OF ONCOLOGY
- Comparative analysis of expression of mutant and wild-type alleles is essential for reliable PCR-based detection of MET exon 14 skipping
- (2019) Natalia V. Mitiushkina et al. BIOCHIMIE
- Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
- (2019) J. Nicholas Bodor et al. CANCER
- Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
- (2019) P. Garrido et al. Clinical & Translational Oncology
- Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society
- (2019) Pathmanathan Rajadurai et al. LUNG CANCER
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- Role of liquid biopsy in oncogene-addicted non-small cell lung cancer
- (2019) Matteo Canale et al. Translational Lung Cancer Research
- Mechanisms of acquired tumor drug resistance
- (2019) Svetlana N. Aleksakhina et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- The genomic landscape of nonsmall cell lung carcinoma in never smokers
- (2019) Bram Boeckx et al. INTERNATIONAL JOURNAL OF CANCER
- Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
- (2019) Jang Ho Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
- (2019) Sylvie Lantuejoul et al. Journal of Thoracic Oncology
- ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib
- (2019) E. Thunnissen et al. LUNG CANCER
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
- (2018) Neal I. Lindeman et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- KRAS: Reasons for optimism in lung cancer
- (2018) C.R. Lindsay et al. EUROPEAN JOURNAL OF CANCER
- Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
- (2018) Jessica J. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
- (2018) Bob T. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
- (2018) Gregory P. Kalemkerian et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS -Mutant Non-Small Cell Lung Cancer: From Biology to Therapy
- (2018) Irene Ferrer et al. LUNG CANCER
- ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties
- (2018) Merrida A Childress et al. MOLECULAR CANCER RESEARCH
- Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
- (2018) Jacqulyne P. Robichaux et al. NATURE MEDICINE
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors
- (2018) Alessia Spagnuolo et al. EXPERT OPINION ON EMERGING DRUGS
- Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice
- (2018) Katsuyuki Hotta et al. International Journal of Clinical Oncology
- Genomic Testing in Lung Cancer: Past, Present, and Future
- (2018) Céline Mascaux et al. Journal of the National Comprehensive Cancer Network
- Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
- (2018) Gonzalo Recondo et al. Nature Reviews Clinical Oncology
- EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts
- (2018) Elena D. Lavdovskaia et al. Oncology Research and Treatment
- HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
- (2018) Y Wang et al. ANNALS OF ONCOLOGY
- Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer
- (2018) Valsamo Anagnostou et al. CANCER RESEARCH
- Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer
- (2018) Jillian Phallen et al. CANCER RESEARCH
- A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
- (2018) Alexander Drilon et al. Cancer Discovery
- Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer
- (2018) Charu Aggarwal et al. JAMA Oncology
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
- (2017) Oliver Gautschi et al. JOURNAL OF CLINICAL ONCOLOGY
- A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib
- (2017) Trish Thorne-Nuzzo et al. Journal of Thoracic Oncology
- Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- (2017) David Planchard et al. LANCET ONCOLOGY
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
- (2017) Michaël Duruisseaux et al. Oncotarget
- Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
- (2016) H. Kadara et al. ANNALS OF ONCOLOGY
- Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer
- (2016) Evgeny N. Imyanitov et al. Molecular Diagnosis & Therapy
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
- (2015) P A Jänne et al. BRITISH JOURNAL OF CANCER
- Novel ALK fusion partners in lung cancer
- (2015) Aglaya G. Iyevleva et al. CANCER LETTERS
- CommonEGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors
- (2015) Noemi Reguart et al. Future Oncology
- Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
- (2015) Oliver Gautschi et al. Journal of Thoracic Oncology
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases
- (2015) Arne Warth et al. VIRCHOWS ARCHIV
- Lung Carcinomas with EGFR Exon 19 Insertions Are Sensitive to Gefitinib Treatment
- (2014) Aglaya G. Iyevleva et al. Journal of Thoracic Oncology
- Detection ofEGFRmutations andEML4-ALKrearrangements in lung adenocarcinomas using archived cytological slides
- (2013) Natalia V. Mitiushkina et al. CANCER CYTOPATHOLOGY
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- A worldwide trend of increasing primary adenocarcinoma of the lung
- (2013) Haruhiko Nakamura et al. SURGERY TODAY
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
- (2012) Marcin Imielinski et al. CELL
- Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
- (2012) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations
- (2012) N. Rekhtman et al. CLINICAL CANCER RESEARCH
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens
- (2012) Satoko Yamamoto et al. Breast Cancer
- High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma
- (2010) Vladimir M. Moiseyenko et al. ONKOLOGIE
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
- (2008) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started